Innovative funding schemes may drive affordability to CVD treatments in Malaysia
IQVIA encouraged finding a balance between optimal CVD care via funding schemes.
Malaysia’s innovative should have funding schemes that can promote affordability and accessibility to optimal cardiovascular care, IQVIA said in its research.
Specifically, innovative funding schemes such as Medical Assistance Funding, Co-Payments, or Patient Assistance Programme (PAP) can be implemented.
“Finding the balance between providing optimal CVD care and achieving long-term health economic benefits via innovative healthcare funding mechanisms is the vital next step for the Malaysian Government to undergo a wellness transformation,” said IQVIA.
Innovative CVD treatments may also prevent hospitalizations and absenteeism in the workplace.
Another way is establishing Cardiovascular Risk Reduction services to manage high-risk patients and improve their CVD risk factors management through integrated care provided by a multidisciplinary team made up of specialists, nurse clinicians, dieticians and pharmacists.
As of 2019, 4-in-10 in all adults in Malaysia had hypercholesterolemia, 3-in-10 had hypertension, and 1-in-5 had diabetes mellitus, read the report.